Safety and Efficacy of HMI-203 in ERT-Treated Adults With MPS II

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 8, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

January 31, 2029

Conditions
Mucopolysaccharidosis II
Interventions
BIOLOGICAL

Genetic HMI-203

HMI-203 delivered intravenously

Trial Locations (6)

22030

Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax

84113

University of Utah Pediatric Genetic & Metabolism Clinic, Salt Lake City

94609

UCSF Benioff Children's Hospital Oakland, Oakland

06519

Yale Center for Clinical Investigation, New Haven

07601

Hackensack University Medical Center, Hackensack

T2E 7Z4

M.A.G.I.C. Clinic, Ltd., Calgary

Sponsors
All Listed Sponsors
lead

Homology Medicines, Inc

INDUSTRY